New pharmacological therapies for the treatment of copd: a review of long-acting muscarinic agonists and long-acting beta-agonists

Authors

  • Edisson Vladimir Maldonado Mariño Universidad Regional Autónoma de Los Andes, Matriz Ambato, Ecuador Author
  • Alex Mauricio Medina Aldaz Médico Cirujano Author
  • Diego Eduardo Guato Canchinia Universidad Regional Autónoma de Los Andes, Matriz Ambato, Ecuador Author
  • Diego Armando Suarez Paez Universidad Regional Autónoma de Los Andes, Matriz Ambato, Ecuador Author

DOI:

https://doi.org/10.59471/ijhsc202497

Keywords:

COPD, treatment, long-acting muscarinic receptors, long – acting beta-agonists, LABA, LAMA

Abstract

Chronic obstructive pulmonary disease (COPD) is characterized by obstruction of the air outlet from the lungs. It is currently recognized as a systemic disease that may be related to other conditions such as cardiovascular and metabolic diseases and cancer. The main treatment of COPD consists of the use of inhaled bronchodilator medications such as long- acting muscarinic antagonists (LAMA) and long- acting beta-agonists (LABA) to improve symptoms and quality of life. At the moment there is no conclusive answer about which is the superior option between LAMA and LABA in the treatment of COPD, however, it is possible to use a combination of both types of drugs, the selection of a particular treatment will depend on various factors, such as disease severity, individual symptoms, response to treatment, and patient preferences.

Downloads

Published

2024-07-22

Issue

Section

Original

How to Cite

1.
Maldonado Mariño EV, Medina Aldaz AM, Guato Canchinia DE, Suarez Paez DA. New pharmacological therapies for the treatment of copd: a review of long-acting muscarinic agonists and long-acting beta-agonists. Interamerican Journal of Health Sciences [Internet]. 2024 Jul. 22 [cited 2024 Dec. 14];4:97. Available from: https://ijhsc.uai.edu.ar/index.php/ijhsc/article/view/97